StageBio Expands Its Global Presence With Acquisition of TPL Path Labs

MT. JACKSON, Va. and FREIBURG, Germany, Oct. 21, 2020 /PRNewswire/ --A StageBio, a leading provider of GLP-compliant necropsy, histology, pathology and specimen archiving services for both preclinical and clinical research,A announced today its acquisition of TPL Path Labs of Freiburg, Germany. The combined organization offers an expanded array of histopathology, molecular pathology, toxicology, digital image analysis and related solutions to biopharma, medical device and academic researchers across the U.S., Europe and beyond. StageBio is a portfolio company of Ampersand Capital Partners.
StageBio Expands Its Global Presence With Acquisition of TPL Path Labs
The acquisition expands StageBio's preclinical and clinical laboratory resources, adding a GLP/GCLP-compliant lab facility and staff in Germany to the company's existing six GLP-compliant lab facilities and two GLP specimen archive sites in the U.S. This strengthens StageBio's ability to deliver services internationally, reducing the need to ship study materials overseas. Uniform technology platforms and protocols across the U.S. and European operations ensure consistent quality, accuracy and efficiency.With more than 175 professionals, including 30 experienced pathologists, the combined organization has the scale to serve the largest multinational customers, while retaining the highly responsive and personalized service for which StageBio is known.Together, StageBio and TPL Path Labs offer an exceptionally broad array of solutions across the preclinical, translational and clinical continuuma??from study protocol development through necropsy, histology, pathology, imaging and analysis. In particular, the acquisition enhances StageBio's ability to support clinical investigators in the areas of biomarker development, tissue cross-reactivity (TCR) and immunohistochemistry.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Декабрь 2020    »